
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors</strong></summary>
            <div>
                <ul><li>- <b>Journal:</b> Aliment Pharmacol Ther. 2024;59:1350–1365.</li><li>- <b>DOI:</b> 10.1111/apt.17980</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recurrence rate of ICI colitis after rechallenge with anti-PD-1/PD-L1 monotherapy?</li><li>- For steroid-refractory ICI hepatitis, what is the typical dose range for mycophenolate mofetil (MMF)?</li><li>- What percentage of patients with biopsy-proven ICI gastritis appear endoscopically normal?</li><li>- What is the median time from ICI initiation to the first elevated lipase value in patients with ICI acute pancreatitis?</li><li>- Infliximab for severe ICI colitis may be dosed higher at 10 mg/kg for what specific clinical condition?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Introduction to Immune Checkpoint Inhibitors (ICIs) & irAEs</strong></summary>
            <div>
                <ul><li>- <b>ICIs:</b> Monoclonal antibodies blocking immune checkpoint receptors (<u>CTLA-4</u>, <u>PD-1</u>, <u>PD-L1</u>).</li><li>- <b>Immune-Related Adverse Events (irAEs):</b> 'Off-target' effects from T-lymphocyte-mediated immune response.</li><li>- <b>Commonly Affected Tissues:</b> Barrier tissues (skin, GI tract, liver, respiratory) and endocrine organs.</li><li>- <b>Onset:</b> Can occur anytime during treatment and even months to years after discontinuation.</li></ul>
                
        <details>
            <summary><strong>ICI Classes</strong></summary>
            <div>
                <ul><li>- <b>CTLA-4 inhibitors:</b> <u>Ipilimumab</u>, <u>tremelimumab</u>.</li><li>- <b>PD-1 inhibitors:</b> <u>Nivolumab</u>, <u>pembrolizumab</u>, <u>cemiplimab</u>.</li><li>- <b>PD-L1 inhibitors:</b> <u>Atezolizumab</u>, <u>avelumab</u>, <u>durvalumab</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diarrhoea, Colitis, and Enteritis</strong></summary>
            <div>
                <ul><li>- Represents a spectrum of colonic inflammation; the most frequent GI toxicity of ICIs.</li><li>- Enteritis can occur with colitis or in isolation.</li></ul>
                
        <details>
            <summary><strong>Epidemiology & Risk Factors</strong></summary>
            <div>
                <ul><li>- <b>Incidence by ICI Class:</b> Combination therapy > CTLA-4 inhibitors > PD-1/PD-L1 inhibitors.</li><li>- <b>Symptom Onset:</b> Typically within a few <q><u>weeks to a few months</u></q> after ICI initiation.</li></ul>
                
        <details>
            <summary><strong>Incidence of Severe (Grade ≥3) Diarrhoea</strong></summary>
            <div>
                <ul><li>- <b>Anti-PD-1/PD-L1:</b> <q><u>1%</u></q> of patients.</li><li>- <b>Anti-CTLA-4:</b> <q><u>6%–8%</u></q> of patients.</li><li>- <b>Combination Therapy:</b> <q><u>10%</u></q> of patients.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk Factors for ICI Colitis</strong></summary>
            <div>
                <ul><li>- <b>Drug-related:</b> Higher <u>ipilimumab</u> dose.</li><li>- <b>Patient-related:</b> Baseline gut microbiota (Firmicutes-enriched), pre-existing IBD/microscopic colitis.</li><li>- <b>Medications:</b> Antibiotic exposure within <q><b>3 months</b></q> prior, NSAID use, chronic proton pump inhibitor (PPI) use.</li></ul>
                
        <details>
            <summary><strong>Protective Factors</strong></summary>
            <div>
                <ul><li>- Vitamin D supplementation may be protective.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Presentation & Complications</strong></summary>
            <div>
                <ul><li>- <b>Symptoms:</b> Loose stools, increased frequency, abdominal cramping/pain, urgency, hematochezia.</li><li>- <b>Complications:</b> Ileus, toxic megacolon, colonic perforation, death.</li><li>- <b>Fatality Risk:</b> Colitis represents <q><b>70%</b></q> of fatal irAEs with anti-CTLA-4 and <q><b>37%</b></q> with combination therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- A diagnosis of exclusion requiring a thorough workup for mimics.</li></ul>
                
        <details>
            <summary><strong>Initial Workup (All Grades)</strong></summary>
            <div>
                <ul><li>- <b>Infectious Studies:</b> <u>C. difficile</u>, bacterial enteric pathogens (NAAT), stool O&P and Giardia antigen if indicated.</li><li>- <b>Lab Tests:</b> CBC, comprehensive metabolic panel, TSH.</li><li>- <b>Stool Markers:</b> Fecal calprotectin is a useful adjunct for mucosal inflammation.</li></ul>
                
        <details>
            <summary><strong>Fecal Calprotectin Utility</strong></summary>
            <div>
                <ul><li>- In patients with transient grade 1 symptoms, a normal fecal calprotectin (<q><b><50 μg/g</b></q>) allows deferral of endoscopy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Endoscopic Evaluation</strong></summary>
            <div>
                <ul><li>- <b>Indicated for:</b> Grade 2-4 symptoms, persistent grade 1 symptoms, or elevated fecal calprotectin.</li><li>- <b>Procedure Choice:</b> Flexible sigmoidoscopy is often sufficient, as <q><u>over 95%</u></q> of cases have left colonic involvement.</li><li>- <b>Upper Endoscopy (OGD):</b> Recommended if lower endoscopy is unrevealing and symptoms persist.</li></ul>
                
        <details>
            <summary><strong>Histopathology Findings</strong></summary>
            <div>
                <ul><li>- <b>Typical ICI Colitis:</b> Active colitis with inflammatory infiltrates (neutrophilic, lymphocytic, or mixed).</li><li>- <b>Other Patterns:</b> Lymphocytic/collagenous colitis, graft-versus-host disease (GVHD)-like pattern with crypt apoptosis.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Imaging</strong></summary>
            <div>
                <ul><li>- <b>Role of CT:</b> Limited diagnostic utility; reserved for suspicion of complications (e.g., perforation, megacolon).</li><li>- <b>CT Performance:</b> Low specificity (<q><b>53%–85%</b></q>) and sensitivity (<q><b>75%–78%</b></q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management (by Severity)</strong></summary>
            <div>
                <ul><li>- Management is guided by CTCAE grading (See Figure 1).</li></ul>
                
        <details>
            <summary><strong>Grade 1 Colitis</strong></summary>
            <div>
                <ul><li>- <b>Initial:</b> Supportive care (hydration, bland diet), bile acid-binding resins. Avoid loperamide.</li><li>- <b>ICI Therapy:</b> Can often be continued.</li><li>- <b>Persistent Symptoms:</b> Trial of oral <b>budesonide</b> <q><u>9 mg daily for 8 weeks</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Grade 2-4 Colitis</strong></summary>
            <div>
                <ul><li>- <b>Action:</b> <u>Withhold/discontinue ICI therapy</u> and consult Gastroenterology.</li><li>- <b>First-line Therapy:</b> Corticosteroids.</li></ul>
                
        <details>
            <summary><strong>Microscopic Colitis</strong></summary>
            <div>
                <ul><li>- Stop potential non-ICI culprit medications (PPIs, NSAIDs, SSRIs).</li><li>- For mild-moderate cases, a trial of <b>budesonide</b> is reasonable before systemic steroids.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Grade 2-3 (Outpatient)</strong></summary>
            <div>
                <ul><li>- <b>Treatment:</b> Oral <b>prednisone</b> <q><u>1 mg/kg/day</u></q>.</li><li>- <b>Taper:</b> Once symptoms improve to grade 1, taper over <q><b>4–6 weeks</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Grade 4 / Systemic Symptoms (Inpatient)</strong></summary>
            <div>
                <ul><li>- <b>Action:</b> Hospitalize for IV therapy.</li><li>- <b>Treatment:</b> IV <b>methylprednisolone</b> <q><u>1–2 mg/kg/day</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Steroid-Refractory Colitis</strong></summary>
            <div>
                <ul><li>- <b>Definition:</b> No improvement after <q><b>3 days</b></q> of IV steroids, or symptom recurrence during taper.</li><li>- <b>Action:</b> Add an IV biologic agent (after screening for viral hepatitis/TB).</li></ul>
                
        <details>
            <summary><strong>Biologic Options</strong></summary>
            <div>
                <ul><li>- <b>Infliximab (TNF-α inhibitor):</b></li><li>- <u>Dose:</u> <q><b>5 mg/kg</b></q> at 0, 2, 6 weeks.</li><li>- <u>Onset:</u> Faster (<q><b>72h to 1 week</b></q>).</li><li>- <u>Indication for higher dose:</u> Consider <q><b>10 mg/kg</b></q> for severe disease or hypoalbuminemia (<q><b><2.5 g/dL</b></q>).</li><li>- <b>Vedolizumab (α4β7 inhibitor):</b></li><li>- <u>Dose:</u> <q><b>300 mg IV</b></q> at 0, 2, 6 weeks.</li><li>- <u>Onset:</u> Slower (<q><b>1-2 weeks</b></q>).</li><li>- <u>Advantage:</u> Gut-selective, less systemic immunosuppression.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Third-line Therapies</strong></summary>
            <div>
                <ul><li>- For colitis refractory to both steroids and initial biologics.</li><li>- <b>Options:</b> <u>Ustekinumab</u>, <u>tofacitinib</u>, fecal microbiota transplantation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Rechallenge and Monitoring</strong></summary>
            <div>
                <ul><li>- Decision to rechallenge depends on prior toxicity severity, ICI class, and oncologic status.</li></ul>
                
        <details>
            <summary><strong>Rechallenge Guidelines</strong></summary>
            <div>
                <ul><li>- <b>Grade 4:</b> <u>Permanent discontinuation</u> of ICI is recommended.</li><li>- <b>Grade 2-3:</b> Rechallenge is possible after resolution.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Recurrence Risk</strong></summary>
            <div>
                <ul><li>- <b>Anti-CTLA-4 monotherapy:</b> Recurrence rate of <q><u>29%</u></q>.</li><li>- <b>Anti-PD-1/PD-L1 monotherapy:</b> Recurrence rate of <q><u>37%</u></q>.</li><li>- <b>Strategy:</b> Consider switching from combination/CTLA-4 regimen to PD-1/PD-L1 monotherapy to reduce risk.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Monitoring</strong></summary>
            <div>
                <ul><li>- Follow-up endoscopy may be offered before resuming immunotherapy.</li><li>- Fecal calprotectin has low sensitivity for confirming histologic remission.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hepatobiliary Toxicity (ICI Hepatitis)</strong></summary>
            <div>
                <ul><li>- Typically presents as asymptomatic liver enzyme elevations with a hepatocellular pattern.</li></ul>
                
        <details>
            <summary><strong>Epidemiology</strong></summary>
            <div>
                <ul><li>- <b>Onset:</b> Median time to onset is <q><u>5–8 weeks</u></q> after ICI initiation.</li><li>- <b>Risk Factors:</b> Combination therapy, first-line immunotherapy, pre-existing liver disease.</li></ul>
                
        <details>
            <summary><strong>Incidence by Therapy</strong></summary>
            <div>
                <ul><li>- <b>Monotherapy (Any Grade):</b> <q><b>3%–7.1%</b></q></li><li>- <b>Monotherapy (Grade ≥3):</b> <q><b>1%–3%</b></q></li><li>- <b>Combination Therapy (Any Grade):</b> <q><b>15%–30%</b></q></li><li>- <b>Combination Therapy (Grade ≥3):</b> <q><b>7.5%–18.8%</b></q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- Requires exclusion of other causes of liver injury (viral, metastatic, biliary obstruction, other DILI).</li></ul>
                
        <details>
            <summary><strong>Monitoring & Workup</strong></summary>
            <div>
                <ul><li>- <b>Monitoring:</b> Monitor LFTs at baseline and every <q><b>2 weeks</b></q> during ICI therapy.</li><li>- <b>Workup:</b> Viral serologies (HAV, HBV, HCV, HEV, EBV, CMV, HSV), review of medications/supplements.</li><li>- <b>Imaging:</b> RUQ ultrasound initially; consider contrasted CT or MRCP.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Biopsy</strong></summary>
            <div>
                <ul><li>- <b>Consider for:</b> Grade ≥3 hepatitis or steroid-refractory cases, especially with atypical features.</li><li>- <b>Utility:</b> Can be useful but may delay treatment. One study found <q><b>11.2%</b></q> of biopsies revealed an alternative diagnosis.</li><li>- <b>Findings:</b> Periportal/centrilobular lymphocytic infiltrates, granulomas. Histologic severity does not correlate with LFT abnormalities.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management (by Severity)</strong></summary>
            <div>
                <ul><li>- Management is guided by CTCAE grading of LFT elevation (See Figure 3).</li></ul>
                
        <details>
            <summary><strong>Grade 1 Hepatitis</strong></summary>
            <div>
                <ul><li>- <b>Action:</b> Continue ICI therapy.</li><li>- <b>Monitoring:</b> Monitor LFTs every <q><b>1–2 weeks</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Grade 2 Hepatitis</strong></summary>
            <div>
                <ul><li>- <b>Action:</b> Temporarily hold ICI.</li><li>- <b>Steroids:</b> If LFTs do not improve in <q><b>3–5 days</b></q>, start <b>prednisone</b> <q><u>0.5–1 mg/kg/day</u></q>.</li><li>- <b>Resumption:</b> May resume ICI when hepatitis is ≤ grade 1 and prednisone is <q><b>≤10 mg/day</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Grade ≥3 Hepatitis</strong></summary>
            <div>
                <ul><li>- <b>Action:</b> <u>Discontinue ICI treatment</u>.</li><li>- <b>First-line Therapy:</b> IV <b>methylprednisolone</b> <q><u>1 mg/kg/day</u></q>.</li><li>- <b>Taper:</b> Taper over <q><b>4–6 weeks</b></q> upon improvement.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Steroid-Refractory Hepatitis</strong></summary>
            <div>
                <ul><li>- <b>Definition:</b> No response after <q><b>3 days</b></q> of steroids.</li><li>- <b>Action:</b> Add a second-line immunomodulator.</li></ul>
                
        <details>
            <summary><strong>Second-Line Agents</strong></summary>
            <div>
                <ul><li>- <b>Preferred:</b> <b>Mycophenolate mofetil (MMF)</b> at a dose of <q><u>500–1000 mg twice daily</u></q>.</li><li>- <b>Other Options:</b> Azathioprine, tacrolimus.</li><li>- <b>TNF-α inhibitors:</b> Generally avoided due to theoretical risk of liver injury.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Rechallenge</strong></summary>
            <div>
                <ul><li>- <b>Guidelines:</b> Recommend permanent discontinuation for grade 3 or 4 hepatitis.</li><li>- <b>Recurrence Risk:</b> If rechallenged, recurrence rate is <q><u>17%–29%</u></q>.</li><li>- <b>Decision:</b> Must be made on a case-by-case basis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ICI Cholangitis</strong></summary>
            <div>
                <ul><li>- <b>Presentation:</b> Rare, marked by a cholestatic pattern of LFTs.</li><li>- <b>Workup:</b> Includes MRCP to evaluate for biliary obstruction.</li><li>- <b>Management:</b> Corticosteroids (<q><b>0.5-2 mg/kg/day</b></q>). High risk of being steroid-refractory, often requiring second-line agents like MMF.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pancreatic Injury</strong></summary>
            <div>
                <ul><li>- Presents variably, from asymptomatic enzyme elevation to acute pancreatitis.</li></ul>
                
        <details>
            <summary><strong>Epidemiology</strong></summary>
            <div>
                <ul><li>- <b>Asymptomatic Hyperlipasemia:</b> Occurs in <q><b>1%–4%</b></q> of patients on ICIs.</li><li>- <b>Symptomatic Acute Pancreatitis:</b> Less common, occurring in <q><b><2%</b></q> of patients.</li><li>- <b>Risk:</b> More common with combination checkpoint blockade.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- Most cases are asymptomatic hyperlipasemia found on routine labs.</li></ul>
                
        <details>
            <summary><strong>Evaluation</strong></summary>
            <div>
                <ul><li>- <b>Onset:</b> Median time to first elevated lipase is <q><u>66 days</u></q> from ICI initiation.</li><li>- <b>Differential:</b> A study showed <q><b>71%</b></q> of hyperlipasemia cases were due to other causes (gallstones, biliary obstruction, colitis).</li><li>- <b>Imaging:</b> Abdominal CT (pancreatic protocol) is advised for lipase <q><b>>3x ULN</b></q>, even if asymptomatic.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>- Management depends on the presence of symptoms and imaging findings.</li></ul>
                
        <details>
            <summary><strong>ICI-induced Acute Pancreatitis</strong></summary>
            <div>
                <ul><li>- <b>Action:</b> Hospitalize, provide supportive care (IV fluids, pain control), and hold ICI.</li><li>- <b>Corticosteroids:</b></li><li>- <u>Grade 2:</u> <q><b>0.5–1 mg/kg/day</b></q> prednisone/methylprednisolone.</li><li>- <u>Severe/Life-threatening:</u> <q><b>1–2 mg/kg/day</b></q> prednisone/methylprednisolone.</li><li>- <b>Taper:</b> Taper over <q><b>4–6 weeks</b></q> after improvement.</li><li>- <b>ICI Rechallenge:</b> Permanently discontinue for severe pancreatitis.</li></ul>
                
        <details>
            <summary><strong>Steroid-Refractory Pancreatitis</strong></summary>
            <div>
                <ul><li>- Limited evidence from case reports suggests potential utility of:</li><li>- <u>Infliximab</u></li><li>- <u>Rituximab</u></li><li>- <u>Azathioprine</u></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Asymptomatic Hyperlipasemia</strong></summary>
            <div>
                <ul><li>- After a thorough workup excludes pancreatitis or other causes:</li><li>- <b>Action:</b> Continue immunotherapy.</li><li>- <b>Treatment:</b> Observe without glucocorticoids.</li><li>- <b>Monitoring:</b> No strong data to support serial lipase monitoring.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Outcomes and Monitoring</strong></summary>
            <div>
                <ul><li>- Patients should be monitored for long-term complications after pancreatic injury.</li></ul>
                
        <details>
            <summary><strong>Long-Term Consequences</strong></summary>
            <div>
                <ul><li>- Recurrent acute pancreatitis.</li><li>- Pancreatic volume loss/atrophy.</li><li>- Endocrine injury (Type 1 Diabetes Mellitus).</li><li>- Exocrine Pancreatic Insufficiency (EPI).</li></ul>
                
        <details>
            <summary><strong>Exocrine Pancreatic Insufficiency (EPI)</strong></summary>
            <div>
                <ul><li>- <b>Incidence:</b> Reported rates of <q><b>3%–4%</b></q> following ICI pancreatic injury.</li><li>- <b>Onset:</b> Median onset was <q><b>390 days</b></q> after the first ICI dose in one study.</li><li>- <b>Management:</b> Responsive to pancreatic enzyme replacement therapy (PERT).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Gastrointestinal Toxicities</strong></summary>
            <div>
                <ul><li>- Includes oesophagitis, gastritis, motility disorders, and coeliac disease.</li><li>- Data is largely limited to case reports and small series.</li></ul>
                
        <details>
            <summary><strong>Oesophageal irAEs</strong></summary>
            <div>
                <ul><li>- <b>Spectrum:</b> Oesophagitis, oesophageal stenosis, oesophagitis dissecans superficialis.</li><li>- <b>Incidence:</b> Rare; found in only <q><b>3%</b></q> of patients undergoing OGD in one cohort.</li><li>- <b>Presentation:</b> Often occurs with concurrent gastritis and/or duodenitis.</li></ul>
                
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>- A diagnosis of exclusion.</li><li>- <b>Initial Therapy:</b> Most patients respond to <u>proton pump inhibitor (PPI)</u> therapy.</li><li>- <b>Refractory Cases:</b> Steroids are reserved for persistent or severe symptoms.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Gastritis</strong></summary>
            <div>
                <ul><li>- <b>Incidence:</b> Constitutes approximately <q><b>5%</b></q> of all luminal GI irAEs.</li><li>- <b>Symptoms:</b> Dyspepsia, bloating. Diarrhea/pain suggests concomitant enterocolitis.</li><li>- <b>Association:</b> Majority of patients with ICI gastritis have concomitant enteritis or colitis.</li></ul>
                
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- <b>Endoscopy:</b> Approximately <q><u>20%–30%</u></q> of patients with biopsy-proven ICI gastritis have a normal endoscopic appearance.</li><li>- <b>Biopsy:</b> Essential for diagnosis, even with unremarkable endoscopy.</li><li>- <b>Differential:</b> Rule out H. pylori, CMV, Crohn's disease, etc.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>- <b>PPIs:</b> Only a minority of patients respond to PPI therapy alone.</li><li>- <b>Glucocorticoids:</b> Nearly <q><u>two-thirds</u></q> of patients require glucocorticoid therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Gastroparesis</strong></summary>
            <div>
                <ul><li>- A very rare irAE.</li><li>- <b>Symptoms:</b> Bloating, dyspepsia, postprandial nausea.</li><li>- <b>Diagnosis:</b> Requires exclusion of mechanical obstruction and other causes; gastric emptying study can confirm.</li><li>- <b>Management:</b> Data on steroids is lacking; case reports show improvement with <u>promotility and antiemetic agents</u> alone.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Coeliac Disease</strong></summary>
            <div>
                <ul><li>- Treatment-emergent coeliac disease has been reported.</li><li>- <b>Presentation:</b> Diarrhea, abdominal pain, villous blunting on histology.</li><li>- <b>Management:</b> Responds to a <u>gluten-free diet</u>.</li><li>- <b>Etiology:</b> Unclear if it is de novo disease or unmasking of subclinical coeliac disease.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Future Directions</strong></summary>
            <div>
                <ul><li>- Recognition and prompt treatment of GI and hepatic toxicities are essential as ICI use expands.</li><li>- Quality prospective, controlled studies are needed to refine management algorithms, risk stratification for rechallenge, and the optimal use of steroid-sparing therapies.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
